392 related articles for article (PubMed ID: 31498003)
1. Modern use of 5-aminosalicylic acid compounds for ulcerative colitis.
Le Berre C; Roda G; Nedeljkovic Protic M; Danese S; Peyrin-Biroulet L
Expert Opin Biol Ther; 2020 Apr; 20(4):363-378. PubMed ID: 31498003
[No Abstract] [Full Text] [Related]
2. Stopping 5-aminosalicylates in patients with ulcerative colitis starting biologic therapy does not increase the risk of adverse clinical outcomes: analysis of two nationwide population-based cohorts.
Ungaro RC; Limketkai BN; Jensen CB; Allin KH; Agrawal M; Ullman T; Colombel JF; Jess T
Gut; 2019 Jun; 68(6):977-984. PubMed ID: 30420398
[TBL] [Abstract][Full Text] [Related]
3. Standard treatment of ulcerative colitis.
Gionchetti P; Rizzello F; Habal F; Morselli C; Amadini C; Romagnoli R; Campieri M
Dig Dis; 2003; 21(2):157-67. PubMed ID: 14571113
[TBL] [Abstract][Full Text] [Related]
4. Conventional therapy for moderate to severe inflammatory bowel disease: A systematic literature review.
Damião AOMC; de Azevedo MFC; Carlos AS; Wada MY; Silva TVM; Feitosa FC
World J Gastroenterol; 2019 Mar; 25(9):1142-1157. PubMed ID: 30863001
[TBL] [Abstract][Full Text] [Related]
5. MMX mesalazine for the induction of remission of mild-to-moderately active ulcerative colitis: efficacy and tolerability in specific patient subpopulations.
Lichtenstein GR; Kamm MA; Sandborn WJ; Lyne A; Joseph RE
Aliment Pharmacol Ther; 2008 Jun; 27(11):1094-102. PubMed ID: 18363894
[TBL] [Abstract][Full Text] [Related]
6. Mesalazine allergy in a boy with ulcerative colitis: clinical usefulness of mucosal biopsy criteria.
Wada S; Kumagai H; Yokoyama K; Ito T; Miyauchi A; Sakamoto S; Imagawa T; Tulyeu J; Tanaka M; Yamagata T
Clin J Gastroenterol; 2016 Oct; 9(5):302-5. PubMed ID: 27503129
[TBL] [Abstract][Full Text] [Related]
7. [Medical therapy of inflammatory bowel diseases: ulcerative colitis].
Lakatos L; Lakatos PL
Orv Hetil; 2007 Jun; 148(25):1163-70. PubMed ID: 17573252
[TBL] [Abstract][Full Text] [Related]
8. Once daily 5-aminosalicylic acid for the treatment of ulcerative colitis; are we there yet?
Lakatos PL; Lakatos L
Pharmacol Res; 2008; 58(3-4):190-5. PubMed ID: 18801439
[TBL] [Abstract][Full Text] [Related]
9. Does the 5-Aminosalicylate Concentration Correlate with the Efficacy of Oral 5-Aminosalicylate and Predict Response in Patients with Inflammatory Bowel Disease? A Systematic Review.
van de Meeberg MM; Schultheiss JPD; Oldenburg B; Fidder HH; Huitema ADR
Digestion; 2020; 101(3):245-261. PubMed ID: 31013494
[TBL] [Abstract][Full Text] [Related]
10. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis.
Wang Y; Parker CE; Bhanji T; Feagan BG; MacDonald JK
Cochrane Database Syst Rev; 2016 Apr; 4(4):CD000543. PubMed ID: 27101467
[TBL] [Abstract][Full Text] [Related]
11. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis.
Feagan BG; Macdonald JK
Cochrane Database Syst Rev; 2012 Oct; 10():CD000543. PubMed ID: 23076889
[TBL] [Abstract][Full Text] [Related]
12. Comparison of mesalazine and balsalazide in induction and maintenance of remission in patients with ulcerative colitis: a meta-analysis.
Rahimi R; Nikfar S; Rezaie A; Abdollahi M
Dig Dis Sci; 2009 Apr; 54(4):712-21. PubMed ID: 18683049
[TBL] [Abstract][Full Text] [Related]
13. [Effectiveness of new, once-daily 5-aminosalicylic acid in the treatment of ulcerative colitis].
Lakatos PL; Lakatos L
Orv Hetil; 2009 Mar; 150(9):397-404. PubMed ID: 19228568
[TBL] [Abstract][Full Text] [Related]
14. Comparative efficacy and tolerability of pharmacological agents for management of mild to moderate ulcerative colitis: a systematic review and network meta-analyses.
Nguyen NH; Fumery M; Dulai PS; Prokop LJ; Sandborn WJ; Murad MH; Singh S
Lancet Gastroenterol Hepatol; 2018 Nov; 3(11):742-753. PubMed ID: 30122356
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and Safety of Beclomethasone Dipropionate versus 5-Aminosalicylic Acid in the Treatment of Ulcerative Colitis: A Systematic Review and Meta-Analysis.
Zhao X; Li N; Ren Y; Ma T; Wang C; Wang J; You S
PLoS One; 2016; 11(8):e0160500. PubMed ID: 27501314
[TBL] [Abstract][Full Text] [Related]
16. Can we move directly from 5-ASA to a biologic agent in ulcerative colitis?
Hindryckx P; Novak G
Best Pract Res Clin Gastroenterol; 2018; 32-33():9-15. PubMed ID: 30060944
[TBL] [Abstract][Full Text] [Related]
17. Modelling the benefits of an optimised treatment strategy for 5-ASA in mild-to-moderate ulcerative colitis.
Louis E; Paridaens K; Al Awadhi S; Begun J; Cheon JH; Dignass AU; Magro F; Márquez JR; Moschen AR; Narula N; Rydzewska G; Freddi MJ; Travis SP
BMJ Open Gastroenterol; 2022 Feb; 9(1):. PubMed ID: 35165124
[TBL] [Abstract][Full Text] [Related]
18. Mesalamine in the treatment and maintenance of remission of ulcerative colitis.
Ham M; Moss AC
Expert Rev Clin Pharmacol; 2012 Mar; 5(2):113-23. PubMed ID: 22390554
[TBL] [Abstract][Full Text] [Related]
19. Balsalazide: a novel 5-aminosalicylate prodrug for the treatment of active ulcerative colitis.
Wiggins JB; Rajapakse R
Expert Opin Drug Metab Toxicol; 2009 Oct; 5(10):1279-84. PubMed ID: 19743890
[TBL] [Abstract][Full Text] [Related]
20. Encapsulated mesalamine granules (Apriso) for ulcerative colitis.
Med Lett Drugs Ther; 2009 May; 51(1312):38-9. PubMed ID: 19448588
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
